Triocim® Capsule: Each capsule contains Cefixime USP equivalent to anhydrous Cefixime 200 mg.
Triocim® 400 Capsule: Each capsule contains Cefixime USP equivalent to anhydrous Cefixime 400 mg.
Triocim® Powder for Suspension: Each 5 ml contains Cefixime USP equivalent to anhydrous Cefixime 100 mg.
Triocim® DS Powder for Suspension: Each 5 ml contains Cefixime USP equivalent to anhydrous Cefixime 200 mg.
Triocim® (Cefixime) is a broad spectrum cephalosporin antibiotic of third generation for oral administration. It is a bactericidal antibiotic and is stable to hydrolysis by many beta-lactamases. It kills bacteria by interfering in the synthesis of the bacterial cell wall. 40-50% of an oral dose is absorbed from gastrointestinal tract, whether taken with meals or not. The plasma half life is usually about 3 to 4 hours and may be prolonged when there is renal impairment. Cefixime is mainly excreted unchanged in bile and urine.
Adult dose: 1 or 2 capsules as a single dose or in two divided doses daily for 7 to 14 days, according to the severity of infection.
Child dose: 8 mg/kg daily as a single dose or in two divided doses for 7 to 14 days according to the severity of infection or age.
No data is available.
Directions for Reconstitution of Suspension
Add 35 ml (7 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. Shake well until all the powder is in suspension.
Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self limiting in nature. Among them diarrhoea, changes in the color of stool, nausea, abdominal pain, dyspepsia, headache, dizziness, elevation of serum amylase may occur.
Triocim® should be prescribed with caution in individuals with a history of gastrointestinal diseases, particularly colitis. Dosage adjustment is only necessary in severe renal failure. In pregnancy no data are available, so it is probably best to avoid using the drug during pregnancy and by the nursing mothers.